Brain Cancer Health Center

Font Size

Childhood Visual Pathway and Hypothalamic Glioma Treatment (PDQ®) - Changes to This Summary (07/21/2006)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

UNTREATED CHILDHOOD VISUAL PATHWAY AND HYPOTHALAMIC GLIOMA

Revised text about spontaneous regressions of optic pathway gliomas reported in children both with and without NF-1 (cited Parsa et al. as reference 6).

Added Combs et al. as reference 11.

Added text about the use of multiagent platinum-based regimens and nitrosourea-based regimens to treat children with progressive optic pathway gliomas (cited Massimino et al. as reference 16).

Revised text about progression-free survival rates for children receiving platinum-based chemotherapy for optic pathway gliomas. Also added text about children with or without NF-1 who receive chemotherapy for optic pathway gliomas.

Added text about a group-wide pilot study of vincristine, carboplatin, and temozolomide for children younger than 10 years with newly diagnosed disease (without NF-1).

WebMD Public Information from the National Cancer Institute

This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER

Last Updated: July 21, 2006

This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.

Some material in CancerNet™ is from copyrighted publications of the respective copyright claimants. Users of CancerNet™ are referred to the publication data appearing in the bibliographic citations, as well as to the copyright notices appearing in the original publication, all of which are hereby incorporated by reference.